[New therapeutic options in chronic hepatitis C virus infection]

Area of Science:

• Hepatology
• Virology
• Pharmacology

Background:

• Chronic hepatitis C virus (HCV) infection is a leading cause of liver disease, cirrhosis, and liver cancer.
• Current pegylated interferon and ribavirin (P+R) therapy achieves sustained viral clearance in less than half of patients.
• The need for more effective HCV treatments is critical.

Purpose of the Study:

• To review clinical studies of new direct-acting antiviral (DAA) agents for HCV treatment.
• To evaluate the efficacy and challenges associated with novel HCV therapies, including boceprevir and telaprevir.
• To assess the impact of DAAs on treatment outcomes and viral resistance.

Main Methods:

• Review of clinical studies involving direct-acting antiviral agents (DAAs) for HCV.
• Analysis of treatment outcomes for triple therapies combining DAAs with P+R.
• Examination of viral resistance patterns associated with DAA use.

Main Results:

• Triple therapies with DAAs (boceprevir, telaprevir) plus P+R demonstrate a 50% higher success rate compared to P+R alone.
• DAA-containing regimens can shorten treatment duration and cure patients with prior treatment failure.
• Rapid development of DAA-resistant viral mutants is a significant concern.

Conclusions:

• New DAAs represent a significant advancement in HCV treatment, improving efficacy and patient outcomes.
• Triple therapy regimens offer a superior treatment option for chronic hepatitis C.
• Managing and understanding DAA resistance is crucial for optimizing future HCV therapy.